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Summary We report the natural killer (NK) and lymphokine activated killer (LAK) cell activities in
peripheral blood lymphocytes (PBL) from untreated patients with Hodgkin's disease (HD) and from healthy
donors. The frequency of LAK cell precursors was also studied using limiting dilution analysis (LDA). About
75% of the HD patients had normal NK activity. There was a higher percentage of low NK responders (mean
percent NK activity of healthy donors - 2 SD) in patients with lymphocyte depletion histologic grade of the
disease and those who were in clinical stage IV, suggesting a correlation of decrease in NK activity with poor
prognosis. We found efficient LAK activity against the NK-sensitive K562 cells and NK-resistant VIP
(melanoma) and T-24 (bladder carcinoma) tumour targets in both low and normal NK responder HD
patients, irrespective of the histopathological grade and clinical stage of the disease. In concordance with their
good LAK cell activity, HD patients showed a frequency distribution of LAK cell progenitors in the PBL
comparable to that of healthy donors.
Hodgkin's Disease (HD) is a malignant lymphoma which is
frequently associated with defective cell mediated immunity
(CMI) and T cell hyporesponsiveness, even at the early stages
and in prognostically better grades of the disease (Aghai,
1986; Romagnani et al., 1985). The possible mechanisms of
impairment of CMI associated with active HD include an
intrinsic defect of T cells, serum inhibitory factors and activa-
tion of suppressor monocytes or lymphocytes. We have
investigated most of these aspects of T cell deficiencies and
their regulation (Gulwani et al., 1986; Karande et al., 1982;
Moghe et al., 1980, 1981; Mukhopadhyaya et al., 1983,
1987a) and also the Interleukin-2 (IL-2) mediated events in
HD (Damle et al., 1990; Gangal et al., 1987; Joshi et al.,
1987; Mukhopadhyaya et al., 1987b).
Amongst the known cellular effector mechanisms, natural
killer (NK) cell activity mediated by large granular lympho-
cytes, is thought to represent the first line of defence against
cancer and viral infections (Lotzova, 1985). Low NK cell
activity has frequently been reported in active HD (Berenyi et
al., 1986; Frydecka, 1985; Hawrylowicz et al., 1982; Levy et
al., 1984; Komiyama et al., 1987; Tursz et al., 1982). The
cytotoxic activity of lymphokine activated killer (LAK) cells,
a promising candidate for adoptive immunotherapy of meta-
static cancers, has been studied in various solid tumours and
in some haematological malignancies like leukemia and non-
Hodgkin's lymphoma (NHL) (Dawson et al., 1986; Oshimi et
al., 1986; Lotzova, 1987; Rajaram et al., 1990; Tatake et al.,
1989) but not so far in HD.
We report here the NK and LAK cell activities of peri-
pheral blood lymphocytes (PBL) from untreated HD patients
classified according to various histopathological grades and
clinical stages. The frequency of LAK cell precursors has also
been studied using limiting dilution analysis (LDA). The
results showed that HD patients generally exhibited normal
NK cell activity with a fall in activity in patients with
lymphocyte depletion grade and those in clinical stage IV.
The LAK activity of PBL from HD patients was efficient
against the LAK susceptible tumour targets and this was
confirmed by their normal LAK cell progenitor frequency.
Materials and methods
Patients and controls
PBL from 65 HD patients (age 12-46 years) and 36 healthy
donors (age 20-50 years) were used for these studies. The
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patients belonged to different histopathological grades of the
disease (Lymphocyte predominance - LP, Nodular sclerosis -
NS, Mixed Cellularity - MC and Lymphocyte depletion -
LD) and were in different clinical stages (I-IV). Their PBL
cytotoxicity was tested before starting treatment.
Controls consisted of healthy donors (either patients'
relatives or laboratory personnel) without any immediate
past history of major illness.
Separation oflymphocytes
PBL were separated on Ficoll-Hypaque (FH) gradient (Phar-
macia, Sweden). The non-adherent PBL were obtained to
assess NK activity as described before (Dabholkar et al.,
1986). LAK cells were generated from the total PBL popula-
tion using the predetermined optimum dose of 10 u recom-
binant IL-2 (rIL-2, Biogen, S.A., Switzerland) per 1 x 106
lymphocytes (Tatake et al., 1989).
Cytotoxicity assay and targets
The NK and LAK cell activities were determined using the
standard four-hour 5"Chromium release assay (Dabholkar et
al., 1986; Tatake et al., 1989). The NK-sensitive targets used
were K562 cells. The NK-resistant monolayer cell lines used
as LAK targets were VIP (melanoma) and T-24 (bladder
carcinoma).
The cytotoxicity assays were done at three effector: target
(E:T) ratios of 50:1, 25:1 and 12.5:1. The results have been
expressed as percent cytotoxicity at E:T = 50:1.
Limiting dilution analysis (LDA)
The frequency of LAK cell progenitors was determined using
LDA as described earlier (Tatake et al., 1989).
Results
NK cell activity
PBL of both healthy donors and HD patients showed a wide
range of NK activity (Figure 1). The mean NK activity of
the HD patients (mean ± S.E. = 42± 3.4) was comparable to
that of healthy donors (45 ± 3). About 25% of the HD
patients were low NK responders (cytotoxicity less than
mean percent cytotoxicity of healthy donors - 2 SD).
An analysis of the NK cell activity in patients with respect
to various histopathological grades showed that the percent-
age oflow NK responders was markedly more in the patients
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Figure 2 NK responder status of HD patients belonging to
various histopathological grades and clinical stages.
Figure 1 NK cell activity of PBL from healthy donors and
patients with active HD.
with LD grade, which has a poor prognostic value (Figure
2). There was also an increased percentage of low NK
responders in patients with stage IV disease (Figure 2).
Although the number of patients belonging to these cate-
gories was small, the data indicate the possibility of a prog-
nostically useful correlation between NK cell response and
disease progression.
LAK cell activity
The PBL from HD patients had somewhat better, but not
significantly higher, LAK cell activity against all three targets
(K562, VIP and T-24 cells) than that of the healthy donors
(Figure 3). As indicated in the figure, even the low NK
responder patients showed good LAK activity. The LAK
cells from both groups showed 0-8% killing of allogeneic
normal PHA transformed blasts used as control targets (data
not shown).
Frequency distribution ofLAK cell precursors
We determined the frequency of LAK cell precursors in PBL
of five healthy donors and five HD patients by LDA. Figure
4 illustrates the data transformed into fitting regression line
plots.
The frequency of LAK cell progenitors in PBL of HD
patients (mean reciprocal frequency ± S.E.
= 1/686 1/
3200) was comparable to that in healthy donors (1/428 1/
2397) which is reflected in their LAK cell function as men-
tioned earlier (Figure 3).
Discussion
Extensive in vivo and in vitro studies conducted on patients
with HD have shown abnormalities in immune functions in
this disease, especially with T cell responses (Aghai, 1986;
Romagnani et al., 1985). Considering this, it is interesting to
note that we showed efficient NK and LAK cell cytotoxic
functions of PBL from untreated HD patients.
In our studies, as in those of Rotstein et al. (1983), most of
the untreated HD patients (75%) were normal NK res-
ponders. A number of patients who showed low NK res-
ponses belonged to LD grade of the disease and clinical stage
IV, indicating that deficiency in NK activity may be
associated with poor prognosis. Also, it was interesting to
note that, of the few patients (n = 7) who could be classified
as high NK responders (cytotoxicity more than mean percent
cytotoxicity of healthy donors + 2 S.D. ) 74% Figure 1)
none had stage IV or LD grade of the disease. Although the
trend of observations indicated association of NK activity
with stage and grade of the disease, owing to the limitation
in the number of patients in these categories available for
studies, no definitive conclusion can be made.
The PBL from a group of ten healthy donors and ten HD
patients were phenotyped for HNK-1 (a NK cell subset
marker) positivity. The percentage of HNK-1 + cells was
comparable in healthy donors (8.3 ± 1.6) and HD patients
(10.9 ± 2.7). This indicates that the low NK activity shown
by 25% of HD patients may not correlate with the percent of
cells bearing NK phenotype.
Most other investigators have reported significantly lower
NK activity in active HD patients (Berenyi et al., 1986;
Frydecka, 1985; Hawrylowicz et al., 1982; Levy et al., 1984;
Tursz et al., 1982; Komiyama et al., 1987) suggesting that the
defect in the killing ability of NK cells in a child with HD
could be due to a deficient release of NKCF. Normal NK
activity has been demonstrated in HD patients in remission
(Berenyi et al., 1986).
In recent years, LAK cells have been considered an impor-
tant cytotoxic effector mechanism, owing to the ubiquitous
presence of LAK cell precursors, the ease with which LAK
cells can be generated in vitro and their broad spectrum of
lytic activity (Grimm, 1986; Rosenberg, 1988). LAK cell
therapy has been tried in solid tumours and in NHL
(Rosenberg, 1988; Rosenberg et al., 1987) but not in HD.
Our data on LAK cell activity showed that the HD
patients exhibited equivalent or better LAK cell activity com-
pared with healthy donors, irrespective of the his-
topathological grade or clinical stage of the disease. Oshimi
et al. (1986) have studied LAK cell generation in lymphomas.
They reported that short-term culture as well as in vitro
expanded LAK cells can efficiently kill autologous and
allogeneic target lymphoma cells. Lymphoma cells of
clinically high grade were shown to be more susceptible to
LAK cell lysis than those of low and intermediate grades. Dawson et al. (1986) have also reported the relative resis-
tance of lymphoma targets to LAK cell killing. There are no
reports, so far, on the susceptibility of Reed-Sternberg cells
to LAK cell lysis.
The frequency of LAK cell precursors in PBL of patients
with lymphomas has not yet been reported. Here we have
shown a comparable frequency of LAK cell progenitors in
healthy donors and HD patients which is in line with their
equivalent LAK cell function.
Therefore, our study reveals that, although HD patients
show T cell hyporesponsiveness, two of the main cytotoxic
effector mechanisms, namely, NK and LAK cell activities,
appear to be efficient in PBL of untreated HD patients.
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Figure 3 LAK cell activity of PBL from healthy donors and patients with active HD.
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Figure 4 Frequency distribution of LAK cell precursors in PBL of healthy donors and patients with active HD.
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